SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022

November 2, 2022

https://www.globenewswire.com/news-release/2022/11/02/2546535/0/en/SELLAS-Life-Sciences-Provides-Webcast-Information-for-Phase-3-REGAL-Study-Update-on-November-14-2022.html

NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provides webcast information for its virtual investor event on November 14, 2022, at 8:30 a.m. ET. at which the Company will provide an update on its Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia.

Read more at globenewswire.com

Related news for (SLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.